共 50 条
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
被引:135
|作者:
Zhou, Jian
Sun, Huichuan
Wang, Zheng
Cong, Wenming
Zeng, Mengsu
Zhou, Weiping
Bie, Ping
Liu, Lianxin
Wen, Tianfu
Kuang, Ming
Han, Guohong
Yan, ZhiPing
Wang, Maoqiang
Liu, Ruibao
Lu, Ligong
Ren, Zhenggang
Zeng, ZhaoChong
Liang, Ping
Liang, Changhong
Chen, Min
Yan, Fuhua
Wang, Wenping
Hou, Jinlin
Ji, Yuan
Yun, Jingping
Bai, Xueli
Cai, Dingfang
Chen, Weixia
Chen, Yongjun
Cheng, Wenwu
Cheng, Shuqun
Dai, Chaoliu
Guo, Wenzhi
Guo, Yabing
Hua, Baojin
Huang, Xiaowu
Jia, Weidong
Li, Qiu
Li, Tao
Li, Xun
Li, Yaming
Li, Yexiong
Liang, Jun
Ling, Changquan
Liu, Tianshu
Liu, Xiufeng
Lu, Shichun
Lv, Guoyue
Mao, Yilei
Meng, Zhiqiang
机构:
[1] Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai
[2] Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai
[3] Department of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
[4] Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang
[5] Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai
[6] Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou
[7] The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
[8] Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou
[9] Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing
[10] Graduate School, Beijing University of Chinese Medicine, Beijing
[11] Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin
[12] Department of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei
[13] Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu
[14] Department of Oncology, West China Hospital, Sichuan University, Chengdu
[15] Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou
[16] Department of General Surgery, Qilu Hospital, Shandong University, Jinan
[17] Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an
[18] The First Hospital of Lanzhou University, Lanzhou
[19] Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai
[20] Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang
[21] Department of Interventional Radiology, Chinese PLA General Hospital, Beijing
[22] Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
[23] Department of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin
[24] Department of Oncology, Peking University International Hospital, Beijing
[25] Department of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou
[26] Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai
[27] Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai
[28] Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai
[29] Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing
[30] Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing
[31] Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou
[32] Institute and Hospital of Hepatobiliary Surgery of Chinese PLA, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing
[33] Editorial Department of Chinese Journal of Digestive Surgery, Chongqing
[34] Department of General Surgery, The First Hospital of Jilin University, Jilin
[35] Department of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
[36] Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing
[37] Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai
[38] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai
[39] Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital Southern Medical University, Guangzhou
[40] Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning
[41] Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai
[42] Department of Interventional Radiology the First Affiliated Hospital of Xinjiang Medical University, Urumqi
[43] Department of Pathology, Tumor Prevention and Treatment Center, Sun Yat-sen University, Guangzhou
[44] Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai
[45] Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine Zhejiang University, Hangzhou
[46] Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin
[47] Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai
[48] Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an
[49] Department of Radiology, West China Hospital of Sichuan University, Chengdu
[50] Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai
关键词:
Primary liver cancer;
hepatocellular carcinoma;
guidelines;
China;
diagnosis;
treatment;
UNRESECTABLE HEPATOCELLULAR-CARCINOMA;
TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;
CONTRAST-ENHANCED ULTRASOUND;
RANDOMIZED CONTROLLED-TRIAL;
STEREOTACTIC BODY RADIOTHERAPY;
PREOPERATIVE TRANSARTERIAL CHEMOEMBOLIZATION;
SIROLIMUS-BASED IMMUNOSUPPRESSION;
VS. RADIOFREQUENCY ABLATION;
SURGICAL RESECTION;
OPEN-LABEL;
D O I:
10.1159/000530495
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background: Primary liver cancer, around 75%-85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China, but also may re-shape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint."
引用
收藏
页码:405 / 444
页数:40
相关论文